First-of-its-kind study targets a female sexual disorder affecting an estimated 9.5 million women in the U.S. alone VANCOUVER, BC, Sept. 27, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, introduces its “Desire Project,” a clinical research program focused on the…


Previous articlePsychedelic Bulletin: Are REMS Patents the Next Frontier in the Psychedelics Patent Skirmish? Johns Hopkins Researcher Scores U.S. Government Grant
Next articleToronto University Health Network Launches Psychedelic Psychotherapy Research Centre